The low level of TGF-β in ITP patients leads to the production of a high level of autoantibodies against autologous platelets because the TGF-β level corresponds to a certain level of regulatory B and T cells that keep the autoimmune response under control [66]. The gene discussed is TGFB1; the disease is autoimmune thrombocytopenic purpura.